Repro-Med Systems Signals Profitable Growth in 2026

Repro-Med Systems, Inc. ((KRMD)) has held its Q4 earnings call. Read on for the main highlights of the call.

Repro-Med Systems, Inc. delivered an upbeat earnings call, underscoring strong growth, regulatory wins and a clear path to sustained profitability. Management acknowledged some execution and timing risks, but emphasized that consistent double‑digit revenue gains, expanding international share and a growing pipeline now outweigh headwinds from project volatility, margin pressure and a modest cash buffer.

Strong Revenue Growth

KORU posted Q4 revenue of $10.9 million, up 23% year over year and marking a third straight quarter of more than 20% growth. Full‑year revenue reached $41.1 million, a 22% increase versus 2024, signaling that the company’s core SCIg franchise is scaling rapidly and building momentum from both new patients and deeper penetration.

Robust International Performance

International Core revenue surged 71% in Q4 and 80% for the full year, highlighting the company’s accelerating traction abroad. European market share roughly doubled from about 10% in 2024 to about 20% in 2025, within an estimated $50 million addressable market that still offers significant runway for further gains.

Domestic Outperformance and Recurring Base Expansion

In the U.S., Domestic Core revenue grew 18% in Q4 and 11% for the year, outpacing the roughly 10% growth of the broader SCIg market in 2025. The global recurring patient base climbed about 20% to roughly 59,000 patients, reinforcing the stickiness and annuity‑like nature of KORU’s consumables‑driven model.

Regulatory and Product Milestones

KORU secured EU MDR certification for its FREEDOM60 system, including compatibility with prefilled syringes, and began shipping the product into the European Union. In January, it also gained 510(k) clearance for RYSTIGGO, its ninth drug on the Freedom platform and second non‑immunoglobulin indication, broadening clinical use and supporting future volume growth.

Pipeline and Pharma Collaborations Expansion

The company’s development pipeline expanded to nine active KORU opportunities, including new deals for a Phase III nephrology program and a Phase I multi‑indication drug. Management expects three commercial‑stage assets—vancomycin, deferoxamine and Phesgo—to be on label within a year, representing an estimated 2.2 million annual infusions and sizeable future revenue potential.

RYSTIGGO Commercial Opportunity

RYSTIGGO is emerging as a meaningful growth vector, with an estimated U.S. opportunity of about 20,000 infusions in 2025 that could exceed 100,000 infusions by 2030. Partner UCB has reported more than 2,400 generalized myasthenia gravis patients globally and about 65% year‑over‑year growth in RYSTIGGO sales, underlining a rapidly expanding addressable pool for KORU’s system.

Profitability and Cash Flow Progress

KORU delivered positive cash flow from operations in Q3, Q4 and for the full year, while ending 2025 with $8.9 million in cash and modest cash usage of $0.7 million. Adjusted EBITDA turned positive at $0.6 million, a 124% improvement year over year, and the company has now posted three consecutive quarters of positive adjusted EBITDA.

Operational Discipline and Margin Resilience

Operating expenses rose just 3% while revenue climbed 22%, demonstrating tangible operating leverage as scale improves. Full‑year gross margin came in at 62.3%, and the company sustained quarterly gross margins above 50% despite headwinds from higher material costs, tariffs and a heavier international mix.

PST / Project Revenue Variability

Project‑based PST revenue remains lumpy, with a 30% year‑over‑year decline in Q4 and a modest decline for the full year, driven by the timing of contract milestones. Management stressed that this variability can skew quarterly comparisons even as the underlying core business trends remain solidly positive.

Gross Margin Pressure from Cost Increases

Q4 gross margin dipped roughly 30 basis points year over year, reflecting inflation in packaging materials and tariff‑related costs. In addition, the strong growth of international sales modestly diluted margins because of geographic mix, though overall profitability held up well given these pressures.

Modest Cash Balance Despite Improvement

While cash flow trends improved in 2025, the company’s year‑end cash balance of $8.9 million remains relatively small for a growth platform. Management highlighted that disciplined spending and ongoing profitability are key to supporting operations and funding initiatives without over‑reliance on external capital.

Execution and Timing Risks to Outlook

The 2026 plan relies on timely prefilled‑syringe conversions, additional 510(k) clearances and stable geopolitical conditions, particularly in the Middle East. Management cautioned that delays in these areas could push some revenue and new‑drug contributions into 2027, especially affecting the upper end of guidance ranges.

Startup Costs for New Production Capacity

KORU is preparing a new production line for its next‑generation pumps, which will carry initial startup costs and could modestly weigh on near‑term margins. The company expects these costs to be offset over time by efficiency gains and enhanced capacity, supporting long‑term margin expansion.

Limited Near-Term Oncology Contribution

Oncology remains a strategic focus, but its financial contribution to 2026 guidance is minimal at this stage. Any material upside will hinge on the timing of regulatory approvals and commercial rollout across cancer indications, leaving this as a medium‑term, rather than immediate, growth driver.

Dependence on Prefilled Syringe Conversions

A significant share of international momentum is tied to pharma‑led conversions to prefilled syringes on the FREEDOM60 platform. Slower rollouts in key regions could meaningfully affect the cadence of international revenue, underscoring the importance of close execution with pharmaceutical partners.

Forward-Looking Guidance and Long-Term Ambitions

For 2026, KORU guided revenue of $47.5–$50.0 million, implying 15%–22% growth, alongside gross margins of 61%–63% and full‑year positive adjusted EBITDA and cash flow, with cash turning positive in the second half. The outlook assumes continued share gains, NRE revenue from at least four collaborations and modest contributions from new clearances, while longer‑term targets remain around $100 million in revenue, gross margins above 65% and EBITDA margins of at least 20%.

KORU’s earnings call painted the picture of a company transitioning from niche player to scaled platform, supported by strong core growth, international expansion and a deepening pipeline. While investors must watch cash levels, cost pressures and execution on prefilled conversions, the trajectory toward sustained profitability and larger market share appears increasingly credible.